ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

ClinicalTrials.gov ID: NCT06125951

Public ClinicalTrials.gov record NCT06125951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 24, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial With an Open-Label Extension Phase to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease

Study identification

NCT ID
NCT06125951
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Actinogen Medical
Industry
Enrollment
247 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Xanamem Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 11, 2024
Primary completion
Sep 30, 2026
Completion
Jan 31, 2028
Last update posted
Apr 22, 2026

2024 – 2028

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
20
Facility City State ZIP Site status
ACW Investigative Site 218 Carlsbad California 92011
ACW Investigative Site 213 Orange California 92866
ACW Investigative Site 209 Sherman Oaks California 91403
ACW Investigative Site 211 Denver Colorado 80218
ACW Investigative Site 208 Englewood Colorado 80113
ACW Investigative Site 203 Delray Beach Florida 33445
ACW Investigative site 201 Miami Florida 33176
ACW Investigative site 202 New Port Richey Florida 34652
ACW Investigative site 204 Orlando Florida 32803
ACW Investigative site 205 The Villages Florida 32162
ACW Investigative Site 207 Decatur Georgia 30030
ACW Investigative Site 206 Toms River New Jersey 08755
ACW Investigative Site 214 Albany New York 12208
ACW Investigative Site 219 Staten Island New York 10314
ACW Investigative Site 210 Dayton Ohio 45459
ACW Investigative Site 217 Independence Ohio 44131
ACW Investigative Site 212 Portland Oregon 97225
ACW Investigative Site 216 East Providence Rhode Island 02914
ACW Investigative Site 220 Austin Texas 78757
ACW Investigative Site 215 Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06125951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2026 · Synced Apr 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06125951 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →